Modulating the TLR4/MYD88/NF-κB signaling pathway can mitigate gut dysbiosis, intestinal membrane disruption, LPS-induced neuroinflammation and impaired cognition in AD mouse models (Zhou et al. 2019; Guo et al. 2020; Su et al. 2023). Here, NFKB1 is linked to Alzheimer disease.